Revance Therapeutics has been granted a patent for an ornamental design of a display screen or portion thereof with a graphical user interface.GlobalData’s report on Revance Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Revance Therapeutics, nanoparticle drug conjugates was a key innovation area identified from patents. Revance Therapeutics's grant share as of June 2023 was 1%. Grant share is based on the ratio of number of grants to total number of patents.
Design patent for a graphical user interface display screen
The granted patent (Publication Number: USD0989790S) pertains to an ornamental design for a display screen or a portion thereof with a graphical user interface. The patent claims that the design is unique and distinct, as shown and described in the accompanying documentation.
The patent does not provide specific details about the graphical user interface or the display screen itself. However, it emphasizes the ornamental design aspect, suggesting that the visual appearance of the interface and screen is the primary focus of the patent.
The granted patent indicates that the design is protected and cannot be replicated or used without permission from the patent holder. This implies that the design has been deemed original and innovative by the relevant authorities.
It is important to note that this patent does not cover the functionality or technical aspects of the display screen or graphical user interface. Instead, it solely focuses on the aesthetic design of these elements.
Overall, this granted patent highlights the significance of visual appeal in the field of display screens and graphical user interfaces. It recognizes the value of unique and visually appealing designs in enhancing user experience and attracting consumers.
In conclusion, the granted patent (Publication Number: USD0989790S) protects the ornamental design of a display screen or a portion thereof with a graphical user interface. While it does not provide specific details about the interface or screen's functionality, it emphasizes the importance of the visual appearance. This patent recognizes the value of unique and visually appealing designs in the field and ensures that the protected design cannot be replicated without permission from the patent holder.
To know more about GlobalData’s detailed insights on Revance Therapeutics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
